Live feed12:15:00·400dPRReleasevia QuantisnowKymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International ConferenceByQuantisnow·Wall Street's wire, on your screen.KYMR· Kymera Therapeutics Inc.Health Care
